Lansoprazole 30mg (DrugBank: Lansoprazole)
7 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
63 | 特発性血小板減少性紫斑病 | 0 |
71 | 特発性大腿骨頭壊死症 | 1 |
85 | 特発性間質性肺炎 | 0 |
98 | 好酸球性消化管疾患 | 0 |
166 | 弾性線維性仮性黄色腫 | 1 |
222 | 一次性ネフローゼ症候群 | 0 |
299 | 嚢胞性線維症 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-UMIN000032412 | 2016/08/21 | 27/04/2018 | Multicenter clinical trial: treatment effect of lansoprazole on non-traumatic osteonecrosis of the femoral head | idiopathic osteonecrosis of the femoral head | Lansoprazole 30mg orally once a day for one year No administration | Sapporo Medical University Hospital | NULL | Complete: follow-up complete | 18years-old | 75years-old | Male and Female | 100 | Phase 2 | Japan |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04660461 (ClinicalTrials.gov) | February 4, 2020 | 3/12/2020 | Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum) | Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum) | Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum) | Drug: Lansoprazole 30mg;Drug: Placebo | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | NULL | Recruiting | 18 Years | N/A | All | 20 | Phase 4 | Spain |